|Bid||249.80 x 300|
|Ask||250.80 x 100|
|Day's Range||250.51 - 253.61|
|52 Week Range||223.02 - 333.65|
|PE Ratio (TTM)||15.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday. Roche said it was investigating a case of Progressive Multifocal Leukoencephalopathy (PML) in a patient previously being treated for three years with Biogen Inc's Tysabri and who had received a single dose of Ocrevus in April. Roche is trying to determine the source of the illness but MS drugs that suppress the immune system can increase the risk of serious infections.
Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.